What Anika Therapeutics, Inc. told the SEC could break it.

Sales depend largely on third-party (Medicare/Medicaid/insurer) coverage and reimbursement; cost-containment initiatives could pressure prices and limit market access.

“Sales of our products are largely dependent upon third-party health insurance coverage and reimbursement, and our performance may be harmed by health care cost containment initiatives or decisions of individual third-party payers.”

Anika's U.S. growth depends on FDA approval of pipeline products; in January 2026 the FDA issued a deficiency letter on its Hyalofast PMA, jeopardizing a >$1B U.S. addressable opportunity.

“We received a letter from the FDA in January 2026 in which the FDA identified a number of deficiencies in which we are preparing our response.”

Anika's sole significant customer, J&J MedTech, was 50% of total product revenue and 55% of accounts receivable in 2025; J&J pricing/volume cuts already drove a $12.6M revenue decline.

“As of December 31, 2025 and 2024, J&J MedTech represented 55 % and 56 %, respectively, of the Company's accounts receivable balance.”

Anika manufactures its entire global commercial supply of HA-based products at one site in Bedford, Massachusetts, so a disruption there would impair its ability to supply all products.

“We manufacture our global commercial supply from a single site located in Bedford, Massachusetts.”

Anika may be unable to find sufficient alternative suppliers in a reasonable time or on commercial terms, which could impair its ability to produce and supply products.

“We may not be able to find sufficient alternative suppliers in a reasonable time period, or on commercially reasonable terms, if at all, and our ability to produce and supply our products could be impaired.”